🇺🇸 FDA
Pipeline program

INBRX-106 - Hexavalent OX40 agonist antibody

Ph 1 Ph 2 INBRX-106

Phase 2 small_molecule active

Quick answer

INBRX-106 - Hexavalent OX40 agonist antibody for Solid Tumor is a Phase 2 program (small_molecule) at Inhibrx Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Inhibrx Biosciences
Indication
Solid Tumor
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials